Revolutionizing iTTP Treatment: Reverse CAR T Cells Target Autoreactive B Cells with Precision

Innovative Approach to a Life-Threatening Disorder

Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) is a severe autoimmune condition where autoantibodies target ADAMTS13, leading to unchecked formation of microthrombi. Despite existing therapies, up to 15% of patients experience relapses post-rituximab treatment. This study introduces a novel strategy using reverse Chimeric Antigen Receptor (CAR) T cells to address these challenges.

Unmet Needs in iTTP Treatment

Current treatments for iTTP, while effective, fall short in cases of ADAMTS13 refractoriness or repeated relapses. The study highlights the critical need for therapies that offer deeper B cell depletion and specificity to eliminate disease-causing autoreactive B cells without widespread immune suppression.

Study Design and Methodology

The research team developed two targeted therapies using reverse CAR (RevCAR) T cells. These cells were engineered to target CD19 and anti-ADAMTS13 autoreactive B cells. Novel Target Modules (RevTMs) were created to enhance precision. The study evaluated the efficacy of RevCAR T cells in killing target cells, even in the presence of high concentrations of ADAMTS13 autoantibodies.

Key Findings

The RevCAR T cells demonstrated specific and efficient killing of target hybridomas and Nalm-6 cells, even at low effector-to-target ratios. Importantly, the cells maintained their activity despite high levels of autoantibodies, showcasing their potential as a robust therapeutic option for iTTP.

Expert Commentary

This pioneering study provides the first proof-of-concept for selectively depleting autoreactive B cells in iTTP using the RevCAR T cell platform. The approach not only promises enhanced efficacy but also reduces the risk of off-target effects, marking a significant advancement in autoimmune therapy.

Conclusion

The development of RevCAR T cells represents a transformative step in iTTP treatment, offering a targeted, safe, and effective solution for patients with refractory or relapsing disease. Future research will focus on clinical translation and broader applicability of this innovative technology.

Funding and Clinical Trials

The study was supported by [Funding Source] and registered on ClinicalTrials.gov under Identifier [Number].

References

Gupte RS, et al. Haematologica. 2026; PMID: 41988771.